Abstract
Recent years have seen major advances in genetic engineering and consequent bacterial production of many interesting and pharmacologically active polypeptides as well as improvements in techniques leading to total chemical synthesis of lower molecular weight peptides such as ‘Zoladex’ (ICI 118630; D-Ser (But)6-Azgly10-LHRH; ‘Zoladex’ is a trade mark, the property of Imperial Chemical Industries PLC). However the therapeutic and commercial potential of polypeptide drugs will only be realised if these advances are accompanied by dosage form design leading to practical and effective formulations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bohn, L., 1975, Compatible polymers, in: “Polymer Handbook”, 2nd Ed., J. Brandrup and E.H. Immergut, eds., John Wiley and Sons, New York.
Furr, B.J.A. and Hutchinson, F.G., 1985, Biodegradable sustained release formulations of the LH-RH analogue ‘Zoladex’ for the treatment of hormone responsive tumours. “EORTC Genitourinary Group Monograph 2, Part A: Therapeutic principles in metastatic prostate cancer”, Alan R. Liss, Inc.
Hutchinson, F.G., 1982, Continuous release pharmaceutical composition. European Patent Application 58481.
Hutchinson, F.G. and Furr, B.J.A., 1985, Biodegradable polymers for the sustained release of peptides, Biochemical Society Transactions, 13: 520.
Mitra, S., Van Dress, M., Anderson, J.M., Peterson, R.V., Gregonis, D. and Feijen, J., 1979, Pro-drug controlled release from poly glutamic acid, Polymer Preparations, American Chemical Society, Division Polymer Chemistry, 20: 32.
Pitt, C.G. and Schindler, A., 1980, The design of controlled drug delivery systems based on biodegradable polymers, in: “Progress in contraceptive delivery systems”, E.S.E. Hafez and W.A.A. van Os, eds., MTP Press, Lancaster.
Robinson, M.R.G., Denis, L., Mahler, C., Walker, K., Stitch, R. and Lunglmayr, G., 1985, An LH-RH analogue (‘Zoladex’) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly injections. Eur. J. Surg. Oncol., 11: 159.
Sidman, K.R., Schwope, A.D., Steber, W.D. and Rudolph, S.E., 1981, Use of synthetic polypeptides in the preparation of biodegradable delivery systems for narcotic antagonists. NIDA Research Monographs, 28: 214.
Walker, K.J., Turkes, A.O., Zwink, R., Beacock, C., Buck, A.C., Peeling, W.B. and Griffiths, K., 1984, Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LH-RH agonist ICI 118630. J. Endocrinol., 103: R1.
Wise, D.L., Fellman, T.D., Sanderson, J.E. and Wentworth, R.L., 1979, Lactic/glycolic acid polymers, in: “Drug carriers in biology and medicine”, G. Gregoriadis, eds, Academic Press, London.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hutchinson, F.G., Furr, B.J.A. (1986). Biodegradable Polymers for Sustained Release of Polypeptides. In: Davis, S.S., Illum, L., Tomlinson, E. (eds) Delivery Systems for Peptide Drugs. NATO ASI Series, vol 125. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9960-6_9
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9960-6_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9962-0
Online ISBN: 978-1-4757-9960-6
eBook Packages: Springer Book Archive